- Home
- MDGL vs BBIO Comparison
MDGL vs BBIO Comparison
Compare MDGL & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDGL
- BBIO
- Stock Information
- Founded
- MDGL 2011
- BBIO 2015
- Country
- MDGL United States
- BBIO United States
- Employees
- MDGL N/A
- BBIO N/A
- Industry
- MDGL Biotechnology: Pharmaceutical Preparations
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- MDGL Health Care
- BBIO Health Care
- Exchange
- MDGL Nasdaq
- BBIO Nasdaq
- Market Cap
- MDGL 6.1B
- BBIO 9.4B
- IPO Year
- MDGL N/A
- BBIO 2019
- Fundamental
- Price
- MDGL $427.05
- BBIO $51.49
- Analyst Decision
- MDGL Strong Buy
- BBIO Strong Buy
- Analyst Count
- MDGL 10
- BBIO 16
- Target Price
- MDGL $474.67
- BBIO $64.44
- AVG Volume (30 Days)
- MDGL 349.9K
- BBIO 2.2M
- Earning Date
- MDGL 10-30-2025
- BBIO 11-11-2025
- Dividend Yield
- MDGL N/A
- BBIO N/A
- EPS Growth
- MDGL N/A
- BBIO N/A
- EPS
- MDGL N/A
- BBIO N/A
- Revenue
- MDGL $515,547,000.00
- BBIO $235,812,000.00
- Revenue This Year
- MDGL $394.12
- BBIO $115.97
- Revenue Next Year
- MDGL $57.74
- BBIO $65.50
- P/E Ratio
- MDGL N/A
- BBIO N/A
- Revenue Growth
- MDGL 3421.98
- BBIO 7.62
- 52 Week Low
- MDGL $200.63
- BBIO $21.72
- 52 Week High
- MDGL $457.16
- BBIO $54.60
- Technical
- Relative Strength Index (RSI)
- MDGL 59.53
- BBIO 53.87
- Support Level
- MDGL $418.36
- BBIO $49.94
- Resistance Level
- MDGL $440.90
- BBIO $54.29
- Average True Range (ATR)
- MDGL 13.53
- BBIO 2.18
- MACD
- MDGL -4.66
- BBIO -0.22
- Stochastic Oscillator
- MDGL 22.40
- BBIO 46.29
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.